Literature DB >> 6982504

Emergency and long-term transesophageal sclerotherapy of bleeding esophageal varices. A prospective study of 50 consecutive cases.

A Alwmark, S Bengmark, B Börjesson, P Gullstrand, B Joelsson.   

Abstract

Fifty consecutive unselected patients with endoscopically proven bleeding esophageal varices were on 76 occasions during 3 years treated with transesophageal sclerotherapy. One-week hemostasis was obtained in 89%, with a hospital mortality of 14%. Three major complications (1.1%) occurred, with one fatal outcome. Long-term repeated sclerotherapy was instituted according to our protocol in all the survivors. During a mean follow-up period of 26 months 19 patients have been treated with sclerotherapy alone, 10 had elective and 2 had emergency operative procedures because of rebleeding. Six fatal bleedings occurred, four after sclerotherapy alone. The 3-year survival is calculated to be 49%. Sclerotherapy has proven to be effective and safe and can be recommended especially in the acute situation. It can also be used as long-term treatment, but rebleedings will in several cases necessitate operative procedures.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982504     DOI: 10.3109/00365528209182077

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  3 in total

Review 1.  Medical treatment of portal hypertension and oesophageal varices.

Authors:  P C Hayes; A N Shepherd; I A Bouchier
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-10

2.  Evaluation of splenic embolization in patients with portal hypertension and hypersplenism.

Authors:  A Alwmark; S Bengmark; P Gullstrand; B Joelsson; A Lunderquist; T Owman
Journal:  Ann Surg       Date:  1982-11       Impact factor: 12.969

3.  Follow-up of patients after variceal eradication. A comparison of patients with cirrhosis, noncirrhotic portal fibrosis, and extrahepatic obstruction.

Authors:  S K Sarin; G Sachdev; R Nanda
Journal:  Ann Surg       Date:  1986-07       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.